We're back from #PEGSEurope where discussions centered on the transformative role of machine learning in antibody drug discovery. We had the chance to hear from: Rebecca Croasdale-Wood, PhD, Senior Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca Andrew Bradbury, MD, PhD, CSO, Specifica, an IQVIA business Charlotte Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC) Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA The panelists emphasized the importance of training ML models on high-quality, targeted datasets to improve predictions for antibody optimization, including binding affinity and developability. In addition to our VP of Antibody Discover, Monica Schwartz presenting our poster, we attended insightful discussions on the latest in de novo design, where computational methods are driving antibody discovery forward. Key themes included integrating in silico methods throughout the discovery pipeline, the importance of both positive and negative data to refine models, and the challenge of advancing from binding predictions to functional outcomes, and more. It was an informative and inspiring week! Special thanks to Twist Bioscience for organizing a wonderful happy hour with scientists from the Weizmann Institute of Science, bringing together innovative minds in the field!?Thank you everyone for a memorable week at PEGS!
Abalone Bio的动态
最相关的动态
-
ASO trafficking through cell membrane modulated by proteins at endosome-Golgi interface… By a CRISPR/Cas9 screening…pooled screen as the primary screening of genome-wide coverage and arrayed screening for validation and confirmation…
New pre-print from our wonderful collaborators at Roche, Genentech, and the Biozentrum, University of Basel, led by Liza Malong, Filip Roudnicky, and Anne Spang. A fun study investigating the molecular mechanisms of gymnosis (a form of cellular uptake) of antisense oligonucleotides (ASOs). Using an improved ASO splice-switch reporter + CRISPR-KO screening, the team identified AP1M1 as a key negative regulator of this mechanism. Many more details in the text, where the team extended findings from the in vitro screens to in vivo validation. This posting is also timely with Ionis Pharmaceuticals, Inc.'s recent approval of Tryngolza for a rare metabolic disorder, speaking to the clinical value of ASOs and the need to further improve the safety, durability, and deliverability of this class of molecules for future therapeutic efforts. There were fun beginnings to this project. Filip (who works at Roche in Basel) performed a short sabbatical in my lab when I was at Genentech (South San Francisco) to execute the foundational CRISPR screens. A great example of cross-institute collaboration within a large, multi-national corporation, and is something I hope other large companies model for their own (and their employees') benefit.
-
If you missed the Introduction to Antibody Engineering course at PepTalk, you still have an opportunity to learn from Andrew Bradbury, Specifica's Chief Scientific Officer. Based off the course that Andrew teaches at PepTalk, this series is broken into 8 distinct videos, ranging from antibody basics and humanization to the processes involved in building antibody libraries, display options, next-gen sequencing, optimization and developability. View the series online at https://lnkd.in/eS3dZfEv.
Antibody Masterclasses - Specifica Inc
https://www.specifica.bio
-
‘???????????? ???????????????????? & ?????????? ?????????????????? ????????????????????????’ Dear network, its a pleasure to announce the next ELRIG UK Forum, taking place at VKU in Berlin, Germany on 18-February-2025. The organizing team has lined up an excellent panel of invited speakers from academia and industry! Don't miss out on this opportunity and join us for this ????????-????-???????????? 1 day Forum: https://lnkd.in/gVc3D3U8 Event Overview: In the rapidly evolving landscape of drug discovery, the identification and validation of novel therapeutic targets are pivotal to expanding the druggable genome and tackling unmet medical needs. This forum focuses on novel targets and the cutting-edge methodologies and technological innovations that are greatly advancing the tractable target space. The forum will bring together leading academic and industry experts to reflect on the latest approaches, opportunities and challenges to exploit historically challenging and novel target classes using state-of-the-art methodologies. Event Speakers: 1) Martin Schr?der - Novartis: Expanding the ligase and target space of TPD 2) Katharina Dürr - OMass Therapeutics: From Molecules to Medicines: Accelerating small Molecule Drug Discovery for challenging Targets using Mass Spectrometry and Cryo-EM 3) Marc Nazare - Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP): Tailoring chemical probes beyond simple small molecule ligands 4) Hauke Cornils - Evotec: A perfect couple: Arrayed CRISPR Screening and High-Dimensional Readouts for Target Identification and Validation 5) Kamyar Hadian - Helmholtz Munich: Drug discovery and drug repurposing using target-based and phenotypic approaches 6) Lukas Friedrich - Merck Healthcare: Industrial Applications of AI-based Methods to Low- and Rich-data regimes in Early Drug Discovery Co-chairs: Susanne Muller-Knapp and Saman Honarnejad
Target Innovation & Novel Screening Technologies – ELRIG’s German Forum
https://elrig.org
-
Global health security, pandemic preparedness | Drug delivery & Nanoparticles | Integrated Product & Innovation Dev. | Scientific Strategy | CMC & GMP Manufacturing | Product lifecycle | Technology Scouting, Partnerships
#BARDA in partnership with National Center for Advancing Translational Sciences (#NCATS), will be conducting the “In silico Drug Discovery,” Workshop to be held on Oct. 23-24, 2024. The workshop is also supported by University of North Carolina at Chapel Hill, and the University of California, San Diego. This workshop will discuss the current state of in silico drug discovery, review best practices for using in silico methods, examine case studies to identify gaps in the translation of in silico models to therapies, and discuss ways to help bridge the gaps in the field. Speakers are pioneers of covered scientific topics. Explore the full agenda here. https://ow.ly/Vwk750SMryh
In silico Drug Discovery Workshop — NCATS
ncats.corsizio.com
-
?? Exciting news from Biocognon! They have been awarded $273,550 by the National Science Foundation (NSF) under the National Science Foundation subagency. This SBIR Phase I award will support their groundbreaking project on a combinatorial platform for discovering improved molecular recognition components for therapeutic and diagnostic antibodies. This innovative research aims to expedite the design and discovery of antibody-based therapeutics, potentially reducing costs and time to market. The project will leverage next-generation DNA sequencing and synthetic biology to create a high-throughput platform for generating better recognition domains. #SBIR #STTR #Innovation ?? The research will demonstrate a novel yeast-based high-throughput screening platform capable of efficiently generating molecular recognition domains that specifically recognize clinically important targets. The project will utilize synthetic biology to construct a library with a rich variety of recognition domains screened against several target antigens. This award reflects NSF's commitment to supporting impactful research. The project will last for 12 months, starting on September 1, 2024, and ending on August 31, 2025. #Biotech #Therapeutics #Diagnostics
-
?? In the Summer 2024 edition of Drug Discovery World, Diana Spencer examines the most recent advancements in high-throughput screening technologies for drug discovery and their potential to expedite therapeutic development: https://ow.ly/cnIH50Stkl3. During her discussion with Shan D., Vice President of Strategy and Innovation at Molecular Devices, Shan emphasizes the significance of automated cell culture and how our CellXpress.ai Automated Cell Culture System offers a solution for researchers that incorporates machine learning to enhance processes like media exchange, plating, passaging, organoid monitoring, endpoint assays, and complex image analysis—ultimately increasing both productivity and reproducibility in drug screening. #3dbiology #3dcellculture #organoids #drugdiscovery #drugscreening #drugdevelopment #diseasemodeling #labautomation #ai #machinelearning #deeplearning #highcontentimaging #highcontentscreening #scienceandtechnology #pharma #geneeditting #cellculture #pdo #imageanalysis #IntheNews
DDW Summer 2024
https://flippingbook.com/
-
Connect with industry leaders at the cutting edge of ?????????? ???????????????? ?????? ???????????????????? at the ???????? ??????????????????’?? & ??????????????????’?? ???????? ?????????????????????? ????????????: ?? With Johnson & Johnson’s Posdinemab receiving FDA fast track designation, discuss the landscape of novel programs in development targeting extracellular and intracellular tau to slow AD progression with Tricia Thornton-Wells (Johnson & Johnson), Xavier Langlois (AbbVie) and Edmond Teng (Genentech) ?? As FDA accepts Annovis Bio, Inc.'s revised Bunetanetap study protocol, hear CEO Maria L. Maccecchini, PhD present how Buntanetap-induced mRNA inhibition has ability to improve movement and function in PD and cognition in AD ?? With GSK and Muna Therapeutics joining forces to identify and validate new AD targets, Manuela Polydoro will share recent progress in Muna’s preclinical efforts to model neuroinflammation in AD and PD, navigating cross-species differences ?? As ADDF invest $10M in Alamar Biosciences, Inc. to advance precision neuroscience, Christopher Bunker, Ph.D., M.B.A. will present cutting-edge developments in their ultra-sensitive NULISA technology to enable early detection and monitoring of neurodegeneration Find out more: https://ter.li/qxw4wt
-
-
Join Carterra and WuXi Biologics at their upcoming symposium in?Oxford, United Kingdom, on June 12th 2024. ? You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include: ? Workflows enhancing the speed or efficiency of drug discovery ? AI and ML initiatives and?in?silico?antibody discovery programs ? Small molecule applications: TPDs, DELs, PROTAC?s, Membrane Proteins ? Novel assay designs including HT-SPR applications ? Emerging modalities such as next-gen antibodies: scFVs, nanobodies, bi-specifics, ADCs ? Strategies to maximize impact in specific therapeutic areas such as immuno-oncology, infectious diseases, and neuroscience Come along to network with your peers. Lunch will be provided. Registration is required as seating is limited: https://lnkd.in/d9W95BWS #molecule #scienceevent #HTS #drugdiscovery
-
-
?? Mark your calendar for October 17th! ?? We’re excited to invite you to a groundbreaking webinar where the Eurofins Discovery Biophysics team and Eurofins CALIXAR unite their expertise to present: "Unprecedented Fragment-Based Screening Using Spectral Shift for GPCRs"! Join our experts—Vanessa Porkolab, Maud Sigoillot, and Alexis Moreno—as they reveal cutting-edge methods for producing and characterizing challenging recombinant proteins like GPCRs, and explore the vital role biophysics plays in hit finding and confirmation. ?? Unlock new possibilities for your research with insights on: - Fragment-Based Screening (FBS): See how fragment-based drug design uncovers novel binding sites on membrane proteins. Using Spectral Shift technology, our team identified antagonist hit fragments for the human adenosine A2A receptor. - Accelerating Drug Discovery: Discover how Eurofins CALIXAR’s GPCR production expertise combined with biophysics technologies can speed up your drug discovery pipeline. - GPCRs & Spectral Shift: Learn how FBS with Spectral Shift technology opens new avenues for finding hidden binding sites on membrane proteins. Don't miss this opportunity to gain cutting-edge insights from the forefront of GPCR drug discovery! Register today and secure your spot: https://lnkd.in/gFN6CDKA #DrugDiscovery #GPCR #FragmentBasedScreening #Biophysics #SpectralShift #PharmaInnovation #Webinar
-
-
?? Transform the Future of Nucleotide Therapeutics – Applied Biophysics Forum 2025 Are you ready to revolutionize lipid nanoparticle development and biophysical characterization for nucleic acid drug delivery? Join us for the Applied Biophysics Forum in Drug Delivery, as we bring together a global community of innovators on 11–12 March 2025 at the Rheingoldhalle, Mainz! This premier workshop, proudly organized by our team in collaboration with industry and academic leaders, dives into the latest advancements and challenges in mRNA and nucleotide therapeutics. This year’s workshop will focus on cutting-edge topics such as: ? The current landscape of lipid-based drug development. ? Biophysical approaches to lipids and nucleic acids. ? Emerging technologies shaping the future of drug delivery. ?? Why attend? ? Learn from case studies and experimental data. ? Dive deep into biophysical and computational tools. ? Showcase your work in our poster exhibition—now with extended sessions! ? Network with peers over refreshments and our on-site buffet dinner. Register now ?? https://bit.ly/4iAlPCK ?? Be part of this transformative event that we’ve curated for the advancement of science in this fast-moving field. #DrugDelivery #LipidNanoparticles #Biophysics
Go Monica!!